ATE282425T1 - Verfahren zur behandlung von endothelialen verletzungen - Google Patents

Verfahren zur behandlung von endothelialen verletzungen

Info

Publication number
ATE282425T1
ATE282425T1 AT97940974T AT97940974T ATE282425T1 AT E282425 T1 ATE282425 T1 AT E282425T1 AT 97940974 T AT97940974 T AT 97940974T AT 97940974 T AT97940974 T AT 97940974T AT E282425 T1 ATE282425 T1 AT E282425T1
Authority
AT
Austria
Prior art keywords
treating endothelial
epo
endothelial injuries
injuries
endothelium
Prior art date
Application number
AT97940974T
Other languages
English (en)
Inventor
Athanasius A Anagnostou
George Sigounas
Original Assignee
Univ East Carolina
Athanasius A Anagnostou
George Sigounas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24861777&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE282425(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ East Carolina, Athanasius A Anagnostou, George Sigounas filed Critical Univ East Carolina
Application granted granted Critical
Publication of ATE282425T1 publication Critical patent/ATE282425T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Materials For Medical Uses (AREA)
  • External Artificial Organs (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT97940974T 1996-09-11 1997-09-10 Verfahren zur behandlung von endothelialen verletzungen ATE282425T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/712,358 US20020052309A1 (en) 1996-09-11 1996-09-11 Method of treating endothelial injury
PCT/US1997/015966 WO1998010650A1 (en) 1996-09-11 1997-09-10 Method of treating endothelial injury

Publications (1)

Publication Number Publication Date
ATE282425T1 true ATE282425T1 (de) 2004-12-15

Family

ID=24861777

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97940974T ATE282425T1 (de) 1996-09-11 1997-09-10 Verfahren zur behandlung von endothelialen verletzungen

Country Status (11)

Country Link
US (5) US20020052309A1 (de)
EP (1) EP0933995B8 (de)
JP (3) JP2001503028A (de)
CN (2) CN1113669C (de)
AT (1) ATE282425T1 (de)
CA (1) CA2265547C (de)
DE (1) DE69731652T2 (de)
DK (1) DK0933995T3 (de)
ES (1) ES2231889T3 (de)
PT (1) PT933995E (de)
WO (1) WO1998010650A1 (de)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2686899B1 (fr) * 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
IL124015A0 (en) 1998-04-08 1999-01-26 Yeda Res & Dev Pharmaceutical compositions comprising a protein
FR2786104B1 (fr) * 1998-11-25 2002-12-27 Centre Nat Rech Scient Inhibiteurs de l'activation de nf-kb, et leurs utilisations pharmaceutiques
PL352223A1 (en) * 1999-04-13 2003-08-11 Kenneth S Warren Inst Modulation of excitable tissue function by peripherally administered erythropoietin
US7309687B1 (en) * 1999-04-13 2007-12-18 The Kenneth S. Warren Institute, Inc. Methods for treatment and prevention of neuromuscular and muscular conditions by peripherally administered erythropoietin
US7345019B1 (en) * 1999-04-13 2008-03-18 The Kenneth S. Warren Institute, Inc. Modulation of excitable tissue function by peripherally administered erythropoietin
US6171620B1 (en) * 1999-04-27 2001-01-09 Health Research, Inc. Method of enhancing the efficacy of anti-tumor agents
CA2372782A1 (en) * 1999-05-11 2000-11-16 Wing Cheung Pharmacokinetic and pharmacodynamic modeling of erythropoietin administration
US20030152562A1 (en) * 2001-10-23 2003-08-14 Yissum Research Development Company Of The Hebrew University Of Jerusalem Vitro micro-organs, and uses related thereto
EP1229934B1 (de) 1999-10-01 2014-03-05 Immunogen, Inc. Zusammensetzungen und verfahren zur behandlung von krebs mittels immunkonjugaten und chemotherapeutischen agenzien
CA2405550A1 (en) 2000-04-12 2001-10-25 Human Genome Sciences, Inc. Albumin fusion proteins
EP1286691B1 (de) * 2000-05-02 2007-11-14 Action Pharma A/S Verfahren zur behandlung von erkrankungen assoziiert mit akuten entzündung unter nichtischämischen zustände
US20020061849A1 (en) * 2000-05-02 2002-05-23 Soren Nielsen Methods for treatment of diseases associated with inflammation under non-ischemic conditions
US20030072737A1 (en) * 2000-12-29 2003-04-17 Michael Brines Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs
US7767643B2 (en) 2000-12-29 2010-08-03 The Kenneth S. Warren Institute, Inc. Protection, restoration, and enhancement of erythropoietin-responsive cells, tissues and organs
US20020169128A1 (en) * 2001-04-09 2002-11-14 Geroge Sigounas Erythropoietin ameliorates chemotherapy-induced toxicity in vivo
EP1930023A3 (de) * 2001-04-09 2008-08-06 East Carolina University Erythropoietin reduziert die Chemotherapie-induzierte in vivo Toxizität
AU2002310122A1 (en) * 2001-05-25 2002-12-09 Human Genome Sciences, Inc. Chemokine beta-1 fusion proteins
EP1459762B1 (de) * 2001-11-02 2008-07-02 Yoshiko Yasuda Verwendung von emp9 zur prävention von proliferativen organerkrankungen
AU2002364586A1 (en) 2001-12-21 2003-07-30 Delta Biotechnology Limited Albumin fusion proteins
GB0211578D0 (en) 2002-05-21 2002-06-26 Univ Belfast Medicaments
DE10234192B4 (de) 2002-07-26 2009-11-26 Epoplus Gmbh Co.Kg Verwendung von Erythropoetin
CA2513213C (en) 2003-01-22 2013-07-30 Human Genome Sciences, Inc. Albumin fusion proteins
KR20070008519A (ko) * 2003-09-29 2007-01-17 워렌 파마슈티칼즈 인코포레이티드 패혈증 및 유착 형성의 치료 및 예방용 조직 보호성사이토카인
EP1686979A4 (de) * 2003-11-07 2010-03-03 Jackson H M Found Military Med Aktivierung von hypoxie-induzierbarer genexpression
DE102004004509B4 (de) * 2004-01-23 2010-07-01 Epoplus Gmbh Co.Kg Einsatz von niedrig dosiertem Erythropoietin zur Stimulation endothelialer Vorläuferzellen sowie zur Organregeneration und Progressionsverlangsamung von Endorganschäden
US20050267027A1 (en) * 2004-04-05 2005-12-01 Lounsbury Karen M Use of erythropoietin for treatment of cancer
US20110076255A1 (en) * 2005-11-07 2011-03-31 Pecora Andrew L Compositions and methods for treating progressive myocardial injury due to a vascular insufficiency
US20080249001A1 (en) * 2006-10-25 2008-10-09 Ajinomoto Co. Inc. Agents that alleviate side-effects caused by chemotherapy agents
RU2426174C1 (ru) * 2010-03-29 2011-08-10 Государственное образовательное учреждение высшего профессионального образования "Курский государственный медицинский университет Федерального агентства по здравоохранению и социальному развитию" Способ фармакологической коррекции ишемии конечности, в том числе при l-name индуцированном дефиците оксида азота
US9533010B2 (en) * 2011-10-31 2017-01-03 Amorcyte, Llc Compositions and methods for treating progressive myocardial injury due to a vascular insufficiency
JP6426693B2 (ja) 2013-03-15 2018-11-21 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー 抗ｃｄ４７薬の処理上有効量を達成するための方法
IL308638A (en) * 2021-05-18 2024-01-01 Attias Eyal Use of erythropoietin or a substance that encourages erythropoiesis, to treat osteomyelitis and bone infection

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6045849B2 (ja) * 1980-08-25 1985-10-12 林原 健 ヒトエリトロポエチンの製造方法
US4745099A (en) * 1985-02-06 1988-05-17 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical composition for the treatment of the anemia of malignant tumors
US5002755A (en) * 1988-02-18 1991-03-26 Vanderbilt University Method of controlling nephrotoxicity of anti-tumor plaintum compounds
JP2632014B2 (ja) * 1988-03-03 1997-07-16 中外製薬株式会社 骨髄機能障害性貧血治療剤
US5716644A (en) * 1992-06-11 1998-02-10 Alkermes, Inc. Composition for sustained release of non-aggregated erythropoietin
JPH0782174A (ja) * 1993-09-17 1995-03-28 Takeda Chem Ind Ltd 抗腫瘍剤
US5626862A (en) * 1994-08-02 1997-05-06 Massachusetts Institute Of Technology Controlled local delivery of chemotherapeutic agents for treating solid tumors
EP0802801A2 (de) * 1994-12-30 1997-10-29 Chiron Corporation Verfahren und zusammensetzungen zur in vivo behandlung der festen tumoren
US5635160A (en) * 1995-06-07 1997-06-03 The University Of North Carolina At Chapel Hill Dinucleotides useful for the treatment of cystic fibrosis and for hydrating mucus secretions

Also Published As

Publication number Publication date
CN1429623A (zh) 2003-07-16
US20020052309A1 (en) 2002-05-02
ES2231889T3 (es) 2005-05-16
CA2265547A1 (en) 1998-03-19
PT933995E (pt) 2005-02-28
US7531501B1 (en) 2009-05-12
EP0933995A4 (de) 2002-08-28
US20080124401A1 (en) 2008-05-29
EP0933995A1 (de) 1999-08-11
CN1235512A (zh) 1999-11-17
JP2001503028A (ja) 2001-03-06
US5922674A (en) 1999-07-13
CN1113669C (zh) 2003-07-09
CA2265547C (en) 2009-12-01
HK1022810A1 (en) 2000-08-25
JP2009196999A (ja) 2009-09-03
DE69731652T2 (de) 2005-12-15
CN1250281C (zh) 2006-04-12
WO1998010650A1 (en) 1998-03-19
US20090285908A1 (en) 2009-11-19
DK0933995T3 (da) 2005-02-14
DE69731652D1 (de) 2004-12-23
EP0933995B1 (de) 2004-11-17
EP0933995B8 (de) 2005-01-19
JP2008133305A (ja) 2008-06-12
US7803408B2 (en) 2010-09-28

Similar Documents

Publication Publication Date Title
ATE282425T1 (de) Verfahren zur behandlung von endothelialen verletzungen
DK0490077T3 (da) Antisense-oligonukleotider til behandling af cancer
PL336788A1 (en) Probucol monoesters in treating circulatory system and inflammatory diseases
DE69826695D1 (de) Arylharnstoffderivate zur behandlung von inflammatorischen oder immunomodulatorischen erkrankungen
DE60142839D1 (de) Botulinum Toxin zur Behandlung von akuten Verletzungen der Skelettmuskeln
ATE258796T1 (de) Verwendung von vitamin d4-derivaten zur behandlung von hauterkrankungen
MY121548A (en) Compounds and methods for the treatment of cancer
DE69434218D1 (de) Photodynamische behandlung von synovium
ATE198706T1 (de) Polyamin-verbindungen zur behandlung von proliferativer erkrankungen
ATE197670T1 (de) Parenterales busulfan zur behandlung von malignen krankheiten
DE69116380D1 (de) Pharmazeutische zubereitung zur behandlung verlängerter gerinnungszeit
BR9500436A (pt) Produtos uso de um g-csf uso de uma proteína tnf ligante processo para o tratamento e/ou prevenção do choque séptico
BR9813318A (pt) Processo de tratamento de tumores e degeneração macular em paciente humano ou veterinário, composição farmacêutica para tratamento de tumores e degeneração macular em um paciente humano ou veterinário
ATE260282T1 (de) Aromatische ester von camptothecinen und verfahren zur behandlung von krebserkrankungen
EA200000242A1 (ru) Применение фанхинона для лечения болезни альцгеймера
PT1237562E (pt) Processo de preparacao de extractos de micania contendo micanolida e di-hidromicanolida e utilizacao no tratamento das doencas proliferativas
DE69924483D1 (de) Kombinationstherapie zur behandlung von tumoren
MXPA00010254A (es) Tratamiento de disfuncion sexual en ciertos grupos de pacientes.
DE69818809D1 (de) Verfahren zur behandlung von narbengewebe
BG101145A (bg) Използване на /s/-аденозил-l-метионин /саме/ i неговите физиологично съвместими соли за лечение нареперфузионно увреждане, причинено от временна фокална исхемиа
ATE225181T1 (de) Verwendung von heparinen niedrigeren molekulargewichtes zur behandlung von hirnödemen
DE3775278D1 (de) Topische methotrexatzubereitung zur behandlung hyperproliferativer epithelerkrankungen.
ATE295731T1 (de) Olanzapine zur behandlung von drogenmissbrauch
BR9713828A (pt) Tratamento de tumores altamente vasculares
DE69635282D1 (de) Behandlung der exzessiven aggressivität mit olanzapine

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0933995

Country of ref document: EP